Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$2.26M-$2.26MN/M vs Q1 2024 EPS Diluted-$9.37-$9.37N/M vs Q1 2024 Operating Income-$1,458,349N/M Operating Cash Flow-$1,660,088N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end